Combined TRIP13 and Aurora Kinase Inhibition Induces Apoptosis in Human Papillomavirus–Driven Cancers
Soma Ghosh1, Tuhina Mazumdar1, Wei Xu1, Reid T. Powell2, Clifford Stephan2, Li Shen3, Pooja A. Shah1, Curtis R. Pickering4,5, Jeffery N. Myers4,5, Jing Wang3,5, Mitchell J. Frederick6, and Faye M. Johnson4,5

ABSTRACT

Purpose: Human papillomavirus (HPV) causes >5% of cancers, but no therapies uniquely target HPV-driven cancers.

Experimental Design: We tested the cytotoxic effect of 864 drugs in 16 HPV-positive and 17 HPV-negative human squamous cell lineages. We confirmed apoptosis in vitro and in vivo using patient-derived xenografts. Mitotic pathway components were manipulated with drugs, knockdown, and overexpression.

Results: Aurora kinase inhibitors were more effective in vitro and in vivo in HPV-positive than in HPV-negative models. We hypothesized that the mechanism of sensitivity involves retinoblastoma (Rb) expression because the viral oncoprotein E7 leads to Rb protein degradation, and basal Rb protein expression correlates with Aurora inhibition–induced apoptosis. Manipulating Rb directly, or by inducing E7 expression, altered cells’ sensitivity to Aurora kinase inhibitors. Rb affects expression of the mitotic checkpoint genes MAD2L1 and BUB1B, which we found to be highly expressed in HPV-positive patient tumors. Knockdown of MAD2L1 or BUB1B reduced Aurora kinase–induced apoptosis, whereas depletion of the MAD2L1 regulator TRIP13 enhanced it. TRIP13 is a potentially druggable AAA-ATPase. Combining Aurora kinase inhibition with TRIP13 depletion led to extensive apoptosis in HPV-positive cancer cells but not in HPV-negative cancer cells.

Conclusions: Our data support a model in which HPV-positive cancer cells maintain a balance of MAD2L1 and TRIP13 to allow mitotic exit and survival in the absence of Rb. Because it does not affect cells with intact Rb function, this novel combination may have a wide therapeutic window, enabling the effective treatment of Rb-deficient cancers.

Introduction

Each year, there are 694,000 new cases of human papillomavirus (HPV)–driven cancers worldwide (1). HPV causes more than 5% of cancers (2), including head and neck squamous cell carcinoma (HNSCC) and squamous cancers of the cervix, anus, penis, and vulva (3). HPV-driven cervical cancer is the leading cause of cancer death in women in the developing world, and the incidence of HPV-positive HNSCC in the developed world is rising (2, 4). The treatment of HPV-positive HNSCC, which usually presents as locally advanced disease, involves a combination of cisplatin chemotherapy and radiotherapy and results in decades-long, chronic, therapy-related adverse effects, including difficulty swallowing, dry mouth, feeding tube dependence, and aspiration pneumonia (5). Consequentially, deintensified therapies and new therapies focusing on druggable targets for HPV-associated HNSCC are being widely investigated with the aim of reducing mortality and treatment-associated morbidity (6).

Several independent investigators have defined the genetic landscape of HPV-positive HNSCC, which is distinct from HPV-negative HNSCC, and have identified potential pathways controlling cell-cycle regulation and constitutive cell proliferation (7, 8). Another distinct molecular feature of HPV-positive cancer cells is that they express the viral oncoproteins E6 and E7, which lead to p53 and retinoblastoma (Rb) protein degradation and thus disrupt cell-cycle regulation and provide a mechanism for tumorigenesis (9). However, none of these findings has translated into improved therapies.

Although HPV-positive tumors are molecularly distinct from HPV-negative tumors, their treatments are identical. In this study, we sought to identify HPV status–selective therapies using a high-throughput drug screen (HTDS) with diverse drugs. We focused on identifying drugs that caused cell death and identified Aurora kinase inhibitors as the only drug class that was consistently more effective against HPV-positive cancers than HPV-negative cancers. We hypothesized that Rb-deficient, HPV-positive cells that overexpress the mitotic checkpoint gene Mad2 (MAD2L1) rely on both TRIP13 and Aurora kinase activity to maintain mitotic fidelity, such that the combined inhibition of TRIP13 and Aurora kinase activity can lead to irreversible mitotic arrest, DNA damage, and apoptosis. Therefore, in this study, we also investigated the roles of Rb, Mad2, and TRIP13 in Aurora kinase inhibition–induced apoptosis in HPV-positive cancers. Our results demonstrate that Rb-deficient cancers are sensitive to Aurora kinase inhibition because of an imbalance between Mad2 and TRIP13. To the best of our knowledge, this is the first study to demonstrate that TRIP13 depletion in combination with Aurora kinase inhibition leads to significantly more apoptosis than does single pathway inhibition selectively in HPV-positive cancers. This finding may lead to the development of novel therapies for the management of Rb-deficient cancers.
Materials and Methods

Cells lines and reagents

HNSCC and cervical squamous carcinoma cell lines were obtained, maintained, and profiled as described previously (10). Tests performed included Reverse Phase Protein Arrays (RPPA; refs. 11, 12), RNA sequencing (RNA-seq; ref. 13), HPV integration (13), and whole-exome sequencing (14). RPPA was performed on 28 cell lines in the HTDS in a single batch to avoid batch effects (11, 12). No RPPA data were available for HN31, UMSCC4, and MDA886LN. Among the clones with the greatest reductions in Rb1 protein expression. The mature antisense sequences were as follows: 5'-TAAAGATG-TATCCATATC-3' (shRb1 #2), 5'-TTAAGCCAATGAAATCAC-3' (shRb1 #4), and 5'-TAGTCCACATGTCCTTC-3' (shRb1 #6).

Immunoblotting

Western blot analysis was performed as described previously (15). In brief, cells were lysed with ice-cold lysis buffer, and the lysates were centrifuged at 20,000 × g for 10 minutes at 4°C. Cell lysates containing equal amounts of protein were resolved using SDS-PAGE, transferred to nitrocellulose membranes, and incubated with different primary antibodies. Protein expression was detected using short tandem repeat analysis, and all were Mycoplasma-free at the time of testing as determined using a Mycoplasma Detection Kit (Lonza). All drugs, except those used in the HTDS, were purchased from Selleck Chemicals and prepared as 10 mmol/L stock solutions in DMSO. Antibodies are listed in Supplementary Table S1.

Apoptosis, cell cycle, and senescence assays

To measure apoptosis, we performed TUNEL staining with an APO-BRDU Kit (BD Biosciences) and annexin V/propidium iodide staining with an FITC Annexin V Apoptosis Detection Kit PE (eBioscience) as described previously (12). For the cell-cycle analysis, cells were harvested, fixed, incorporated with bromodeoxyuridine (BrdU), and stained with 7-aminoactinomycin D using a BrdU Flow Kit (BD Biosciences). Data were acquired with a 3-laser, 10-color Gallios flow cytometer (Beckman Coulter) and analyzed using Kaluza software, RRID:SCR_016182 (Beckman Coulter). Assays were performed in triplicate, and each test was completed twice on different days. To measure senescence, we stained cells using the CellEvent Senescence Green Detection Kit (Thermo Fisher Scientific). Briefly, after drug treatment, cells were incubated with Senescence Green Probe, a fluorescence-based reagent that contains two galactoside moieties that make it specific to β-galactosidase. The enzyme-cleaved product is retained within the cell and emits a fluorescent signal that we measured at 490/514 nm using a flow cytometer.

siRNA transfection

siRNA molecules (5 nmol/L, GE Dharmacon; 5 nmol/L, Santa Cruz Biotechnology, Inc.) targeting E7, TRIP13, MAD2L1, and BUB1 or scrambled controls were transfected into cells using lipofectamine RNAi Max (Thermo Fisher Scientific) in Opti-MEM (Invitrogen) according to the manufacturers’ standard protocols. Cells were transfected with siRNA for 24 hours prior to the initiation of drug treatment.

Generation of stable cells using lentiviral infection

The lentiviral-based shRNA (GIPZ plasmid) used to knockdown human RBP1 expression was purchased from Horizon Discovery. On the basis of the knockdown efficiency of Rb1 protein expression in three HPV-negative cell lines (HN31, UMSCC4, and MDA88 6LN), we selected three shRb1 clones (#2, #4, and #6) for this study. These clones had the greatest reductions in Rb1 protein expression. The mature antisense sequences were as follows: 5'-TAAAGATG-TATCCATATC-3' (shRb1 #2), 5'-TTAAGCAAATGAAATCAC-3' (shRb1 #4), and 5'-TAGTCCACATGTCCTTC-3' (shRb1 #6). To generate lentivirus-expressing shRNA for Rb1, we transfected HEK 293T cells with GIPZ-nonsilence (for the vector control virus) and GIPZ-shRb1 with jetPEI transfection reagent (RRID:CVC CL_0063). The medium was changed 24 hours after transfection and then collected every 48 hours thereafter. The collected lentivirus-containing medium was centrifuged and then filtered (0.45 μm). Cells were seeded at 50% confluence 12 hours before infection, and the medium was replaced with a medium containing lentivirus. After 24 hours, the medium was replaced and the infected cells were selected with 2.5 μg/mL puromycin (Sigma-Aldrich).

In vivo tumor growth study

The in vivo tumor growth study was performed in accordance with the Guide for the Care and Use of Laboratory Animals of the NIH and approved by MD Anderson’s Institutional Animal Care and Use Committee. The PDX models were generated as described previously (17) and subjected to qPCR as described to determine the HPV type (18, 19). Briefly, tumor tissue was cut into small fragments (5–6 mm) and implanted subcutaneously into the flanks of nude mice. The skin incisions were closed with skin clips that were removed after 10 to 15 days. Once tumors reached an average of 150 to 300 mm³, the mice were randomized into either vehicle group or alisertib group. Alisertib (Takeda Pharmaceuticals; 10 mg/kg in 10% β-cyclodextrin) was administered via oral gavage once daily on a weekly schedule of 6 days on and 1 day off. Tumors were monitored daily, and tumor volume (length × width² × 0.5) was evaluated twice per week with digital calipers. Mice were euthanized when tumors reached 2,000 mm³. The endpoint for the survival studies was the tumor burden. Survival was measured using the Kaplan–Meier method (20). Survival curve analysis was performed with GraphPad Prism software version 9 (RRID:SCR_002798).
Genomic data from TCGA cohorts
Files containing raw RSEM count data from The Cancer Genome Atlas (TCGA) RNA-seq datasets that were previously harmonized computationally and mapped through the Toil open source calling pipeline (21) were downloaded from Amazon web services (AWS) S3 as previously described. RSEM counts were normalized to get upper quartile FPKM values (FPKM-UQ) with an in-house script in R studio. Essentially, non-protein coding RNAs were removed using annotations from Ensembl, which left 19,345 genes. The 75th percentile RSEM value (excluding zeros) for each TCGA sample was calculated and used to derive FPKM-UQ values. For most statistical analyses, the log 2 (FPKM-UQ – 0.01) transformation was applied.

A total of 517 RNA-seq samples from HNSCC tumors were acquired (7) using original TCGA marker approach. Detection of HPV infection and HPV integration and measurement of HPV gene expression in TCGA data sets were performed by applying the VirusSeq pipeline RRID:SCR_005206 (22). Tumor HPV status was established by considering an empirical cutoff of 1,000 read counts mapped against the viral genome (23).

Statistical analyses
We computed the concordance correlation coefficient to assess the reproducibility of the normalized growth rates of the two replicates. To determine whether drugs of the same target class cluster together because of similar drug potency, we performed unsupervised drug clustering based on AOC_LD values. In the clustering analysis, we observed six distinct drug clusters based on the clustering trees. We then applied chi-square test to compare drug classification and the cluster membership. We also applied the Fisher exact test to compare mutations status (wild-type and mutant) and drugs' response data (sensitive and resistant). In these analyses, P ≤ 0.05 was considered statistically significant.

To identify protein markers, we compared RPPA protein expression levels between drug-sensitive and drug-resistant groups using 2-sample t tests. We used the Benjamini–Hochberg method to adjust for multiple hypothesis testing. We used an appropriate FDR q value to identify protein markers significantly associated with drug-sensitive or drug-resistant groups. All statistical and bioinformatical analyses were performed using R (version 3.6.0).

Data availability statement
The data generated in this study are available within the article and its Supplementary Data files. Any data used in this study that is not included in the paper or supplementary files can be made available upon request from the corresponding author.

Results
Landscape of drugs that cause cell death in squamous carcinoma
We tested the effects of 864 unique drugs from 51 classes (Supplementary Table S2) in 16 HPV-positive and 17 HPV-negative HNSCC and cervical squamous cancer cell lines (Supplementary Table S3) that we characterized previously (13). Drugs without a well-defined target or with unique targets (i.e., targets not shared with other drugs in the screen) were categorized as “other.” As with our previous HTDS (12), the quality control metrics showed that the data were reproducible (Supplementary Fig. S1).

Because traditional methods of measuring drug sensitivity (e.g., calculating IC50 values) can be confounded by the number of cell divisions during the course of an assay, we adapted an alternative method whose results are independent of the cell division rate (24). In this method, the area-over-the-curve lethal dose (AOC_LD) value is 0 when a drug does not kill cancer cells at any concentration and greater than 0 when cell death occurs; it has a maximum value of 1 (Supplementary Fig. S2A).

About half the drugs tested (n = 425; 49%) had AOC_LD values of 0, and thus were ineffective, in all cell lines. The rest of the drugs (n = 439; 51%) were potentially effective, as they led to cell death in at least one cell line. To determine if certain classes of drugs were more or less likely to lead to cell death, we determined if drugs within each class were enriched in either the ineffective or effective categories by calculating the Pearson residual for each class (Supplementary Fig. S2B).

Most drug classes were enriched with either effective or ineffective drugs, providing evidence that drugs with the same targets had similar effects. Anthracyclines, vinca alkaloids, and all drugs targeting Aurora kinases, histone deacetylase (HDAC), microtubules, pyruvate dehydrogenase kinase 1 (PDK1), FGFR, CDC7, Bruton tyrosine kinase (BTK1), or the proteasome were effective, whereas those targeting matrix metalloproteinase, nitrogen oxide synthetase, or PARP were ineffective. To determine whether effective drugs within the same target class cluster together, we performed unsupervised drug clustering of the effective drugs using their AOC_LD values (Supplementary Figs. S2C and S2D).

About half of the chemotherapy agents we tested were effective (43/78; 55%). To further classify the effectiveness of these chemotherapy agents, we divided them into seven categories based on their mechanisms. The taxanes, anthracyclines, topoisomerase inhibitors, and vinca alkaloids were almost universally effective, whereas most of the alkylating agents and platinum drugs were largely ineffective (Supplementary Fig. S2B). Unsupervised clustering of the effective chemotherapy drugs according to their AOC_LD values demonstrated that drugs in the same category were more likely to cluster together than to cluster with drugs in a different class (Supplementary Figs. S3A and S3B). Likewise, we divided the drugs targeting the PI3K/AKT/mTOR pathway into seven categories based on their targets. Most mTOR and PDK1 inhibitors were effective, and the drugs in the other categories had variable efficacy (Supplementary Fig. S2B). Drugs did not strongly cluster by target within the PI3K/AKT/mTOR group (Supplementary Figs. S3C and S3D) likely because of off-target effects and target overlap.

Aurora kinase inhibitors are effective against HPV-positive cancers
To determine if any drug or drug class was more effective than the others against HPV-driven cancers, we first compared the number of HPV-positive and -negative cell lines that were sensitive to the 439 effective drugs to the number of HPV-positive and HPV-negative cell lines that were resistant. Only 30 (7%) of the effective drugs had a differential effect based on HPV status, and only one class of drugs, the Aurora kinase inhibitors, was significantly more effective in HPV-positive cell lines (P < 0.05, Fisher exact test; Fig. 1A and B).

Drugs from 15 classes were more effective in HPV-positive cell lines than in HPV-negative cell lines (Supplementary Table S4). We closely examined all the effective drugs in each of these 15 classes to determine if there was a trend for a class effect that warranted further investigation (Supplementary Fig. S4A). Drugs from two of these classes (antimetabolites and MAPK inhibitors) had variable effects, with some drugs more effective in HPV-negative cell lines and others more effective in HPV-positive cell lines. Most drug classes (antimetabolites and inhibitors of CDK, PKC, PDGFR/KIT, MAPK, proteasome, JAK/STAT, PI3K/AKT/mTOR, topoisomerase, or VEGFR) did not demonstrate a class effect, as a minority of the drugs in these classes...
demonstrated a differential effect based on HPV status, and the direction of the effect was variable within the class. We did not study several drug classes (BTK, ATM, and metabolism inhibitors) further because of their overall lack of class efficacy. Within the large family of PI3K/AKT/MTOR inhibitors, several mTOR inhibitors were more effective in HPV-positive cell lines than in HPV-negative ones, but the overall efficacy of these drugs was low with the exception of Torin-2, which has several off-target effects at a concentration of 3.16 μmol/L. The more specific mTOR inhibitors—everolimus, rapamycin, and ridaforolimus—caused cell death only in a single cell line at concentrations known to inhibit mTOR (11, 25). Likewise, drugs affecting microtubules were consistently more effective in HPV-positive cell lines, but in contrast to the mTOR inhibitors, every drug in the microtubule/taxane class caused cell death in most of the cell lines tested, including the HPV-negative cell lines. Only one microtubule/taxane was significantly more effective in HPV-positive than in HPV-negative cell lines. Consistent with our findings, taxanes have been shown to have broad clinical efficacy in squamous cancers (26, 27).

All 16 Aurora kinase inhibitors tended to be more effective in HPV-positive cell lines, although the difference was statistically

Figure 1.
Aurora kinase inhibitors are effective in HPV-positive squamous carcinoma cell lines. A, The differential efficacies of 439 effective drugs based on HPV status were compared. Only 30 drugs (left column) demonstrated a significantly different effect ($P \leq 0.05$). The number in each cell corresponds to the number of drugs in each category, and the color of each cell corresponds to the standardized Pearson residual measuring the strength of enrichment for the drugs allocated to each category. Orange indicates enrichment. Blue indicates depletion. The histogram on the left shows the hypergeometric log$_{10} P$ values; the red dashed line indicates $P = 0.05$. B, The hypergeometric log$_{10} P$ values for 439 drugs are shown for the drugs divided into 39 categories. The dashed red line indicates $P = 0.05$. C, AOC_LD values for 2 Aurora kinase inhibitors, alisertib and barasertib. The AOC_LD values were used as continuous variables, and cell lines were grouped by HPV status. Box plots show the median AOC_LD levels and 95% confidence intervals across all cell lines in each category. Each data point represents one cell line.
Aurora kinase inhibition induces cell death in HPV-positive but not HPV-negative squamous carcinoma cell lines in vitro. A, Bromodeoxyuridine (BrDU)-TUNEL assays were used to measure apoptosis with flow cytometry in three HPV-positive and three HPV-negative squamous carcinoma cell lines treated with 50 nmol/L barasertib or 200 nmol/L alisertib for 72 hours (left) or 2 doubling times (right). BrdU positive apoptotic cells were detected and quantified. The bar graph indicates the percentages of apoptotic cells with fragmented DNA in HPV-positive and HPV-negative cell lines. Values are the means ± SD for three independent experiments. B and C, Immunoblots of cleaved PARP (Cl. PARP) and cleaved caspase-3 (Cl. Caspase-3) levels in three HPV-positive and three HPV-negative cell lines after barasertib or alisertib treatment for (B) two doubling times or (C) 72 hours. D, We used flow cytometry to detect and quantify senescent cells in four HPV-positive and five HPV-negative cell lines treated with 50 nmol/L barasertib or 200 nmol/L alisertib for 72 hours ("***", P ≤ 0.005; "****", P ≤ 0.0001 (unpaired, two-tailed Student t test)). UM47, UMSCC47; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
significant for only seven of them when we used AOC_LD as a dichotomous variable (Fig. 1C). Three other drugs in the HTDS also inhibited Aurora kinases: the JAK3 inhibitor AT9283, the CDK2 inhibitor JNJ7706621, and hesperidin, which inhibits multiple targets. All three drugs were more effective in HPV-positive than in HPV-negative cell lines (Supplementary Fig. S4B). Likewise, when AOC_LD was used as a continuous variable, the difference was statistically significant (P ≤ 0.05, Wilcoxon test) for seven of the Aurora kinase inhibitors and for hesperidin, AT9283, and JNJ7706621 (Supplementary Fig. S4C). In addition to the AOC_LD values, we computed the IC50 values of all 16 Aurora kinase inhibitors in HPV-positive cell lines (Supplementary Figs. S4D and S4E). Similar to our AOC_LD metric, most IC50 values for Aurora kinase inhibitors are low in HPV-positive cell lines.

**Aurora kinase inhibitors cause apoptosis in HPV-positive cancer cells**

To confirm that Aurora kinase inhibition led to cell death in HPV-positive cell lines, we examined the effect of two clinically relevant and specific drugs, alisertib (28) and barasertib (29), on apoptosis using three orthogonal methods and relevant drug concentrations. In addition to using a standard treatment time of 72 hours, we also treated the cells for two doubling times to overcome the artifact of a fixed treatment time for cell cycle-specific drugs in cell lines with diverse cycling times (24, 30). TUNEL-positive apoptotic nuclei significantly increased in HPV-positive cancer cell lines (UMSCC47, CaSkii, and M5751) treated for 72 hours or two doubling times. However, no appreciable levels of apoptosis were noted in matched HPV-negative cancer cell lines (UMSCC19, FaDu, and HN31). Likewise, apoptosis induced by barasertib or alisertib was associated with caspase-3 activation and PARP cleavage in HPV-positive cancer cell lines (Fig. 2B and C). In contrast, no significant differences in senescence induced by Aurora kinase inhibitors were noted between HPV-positive cells and HPV-negative cells (Fig. 2D).

To test the effect of Aurora kinase inhibition in vivo, three patient-derived xenograft (PDX) models that were derived from patients with p16-positive oropharynx cancer [HOSC144 (HPV16, HPV32), HOSC19 (HPV18, HPV39), and HOSC 156 (HPV18)] were implanted in nude mice. We administered a low dose of alisertib (10 mg/kg) continuously for 3 weeks. In agreement with the in vitro findings, clear evidence of tumor regression was observed in both PDX models. This antitumor effect was accompanied by a concordant increase in survival duration (Fig. 3A–C). In addition, we also tested an HPV-negative cell line with high Rb protein levels and observed that it was resistant to alisertib treatment (Fig. 3D). Also, a sustained response was observed even after treatment was stopped. Tumors collected from alisertib-treated mice on days 8 and 21 had significantly lower levels of Ki67 staining and increased levels of cleaved caspase-3 compared with those from vehicle-treated mice (Fig. 3E and F).

**Rb expression and TP53 mutations predict cells’ response to Aurora kinase inhibitors**

To determine if factors other than HPV status predict response to Aurora kinase inhibitors, we compared protein expression using RPPA and gene mutation using whole-exome sequencing to drug efficacy using AOC_LD. The expression levels of 19 proteins were correlated with sensitivity to at least four Aurora kinase inhibitors (Supplementary Fig. S5A) after correction for multiple testing (P ≤ 0.05, adjusted for the FDR). We used immunoblotting to validate the RPPA findings in all 33 cell lines. Among the 19 proteins, we focused on the 8 that correlated with sensitivity to the most drugs and in which the correlations were consistently in a single direction (i.e., expression predicted sensitivity or resistance but not both). On the basis of published studies (30, 31), we also used immunoblotting to explore seven additional candidate proteins that were not in our RPPA. Of the 15 chosen proteins, we were able to detect distinct immunoblotting bands for all except Tau. Only Rb, pRb (S807/811), and p16 were consistently correlated with drug sensitivity (P ≤ 0.05 per the Wilcoxon test; Fig. 4A; Supplementary Figs. S5B, S5C, and S6; some data not shown). Specifically, the expression of pRb (S807/811) determined using RPPAs or immunoblotting, total Rb determined using immunoblotting, and p16 (CDKN2A) determined using immunoblotting were correlated with the efficacy of all the Aurora kinase inhibitors, with statistical significance in 6, 6, 10, and 7 of the drugs, respectively (Supplementary Figs. S5C and S6; some data not shown). In addition, we also compared with the pRb levels with sensitivity (AOC_LD) to 15 Aurora kinase inhibitors in only the HPV-positive cell lines. Although pRb (S807/811) expression is consistently lower in sensitive cell lines, the result did not reach statistical significance likely due to the low sample size (Supplementary Fig. S6C).

We determined the extent to which drug sensitivity was correlated with 50 of the most common gene mutations in HNSCC (7). Only 35 of the 50 gene mutations were found in two or more cell lines in the HTDS. Of those 35 gene mutations, only TP53 mutations were correlated with resistance to seven Aurora kinase inhibitors (Supplementary Fig. S7A). Aurora B mRNA, Aurora B protein, and Aurora A mRNA expression did not correlate with Aurora kinase inhibitor efficacy (representative data, Supplementary Fig. S7B).

**Manipulation of Rb1 affects Aurora kinase inhibition–induced apoptosis in squamous cancers**

To determine if Rb protein expression is instrumental in Aurora kinase inhibitor–induced apoptosis, we used three independent methods to alter Rb expression in HPV-negative squamous cancer cell lines. First, we treated HPV-negative cells with alisertib and depleted the Rb levels using transient transfection (Supplementary Fig. S8A). Rb depleted HPV-negative cells showed an increase in cleaved PARP levels upon treatment with alisertib. Next, we moved to a more stable system and knocked down Rb using short hairpin RNA (shRNA) that significantly reduced Rb protein expression in three HPV-negative cell
The hypothesis that Mad2 and BUB1B mediate Aurora kinase activity to promote mitotic exit and survival create an Achilles heel for cancer cells lacking Rb because these cells have elevated levels of Mad2 (34). The primed mitotic checkpoint complex (MCC) may proteolytically cleave BUB1B and prolong mitosis (30, 32).

In normal cells, prolonged mitosis resulting from Mad2 overexpression can lead to G2 arrest or mitotic cell death (37, 38), so it is unclear why Mad2 overexpression is tolerated in HPV-positive cancers. One potential mechanism to prevent stalled mitosis is the regulation of Mad2 function via TRIP13. We hypothesized that HPV-positive cells have an increased dependency on TRIP13 for their mitotic exit. Therefore, we induced the transient overexpression of TRIP13 in 2 HPV-positive cell lines and observed a partial rescue from alisertib-induced apoptosis as indicated by PARP and caspase-3 cleavage (Fig. 4B) and annexin V expression (Fig. 5C). Similarly, TRIP13 overexpression in 2 HPV-negative cell lines with RB1 knockout (done with shRNA) reduced apoptosis caused by Aurora kinase inhibition (Fig. 5D).

MCC gene expression has never been examined in HPV-positive tumors. To determine if MCC genes are overexpressed in HPV-driven cancers, we examined their expression in tumor samples from 517 patients with HNSCC in the TCGA (7). We compared mRNA expression between 70 HPV-positive and 447 HPV-negative tumors and found significantly higher expression of both BUB1B and MAD2L1 in HPV-positive tumors (P < 0.0001; Fig. 6A). We also compared only HPV-positive (n = 51) and HPV-negative oropharynx squamous cell carcinoma (OPSCC; n = 28) and found significantly higher expression of both BUB1B and MAD2L1 in HPV-positive OPSCC tumors, P < 0.005 (Fig. 6A, right).

The expression of TRIP13 was lower in HPV-positive than in HPV-negative OPSCC, but the difference was not significant in both the sample sets. Specific case IDs for groups of TCGA patients with HNSCC and OPSCC are provided in Supplementary Tables S5 and S6.

Next, we determined if TRIP13, MAD2L1, and BUB1B expression predicted response to Aurora kinase inhibition in HPV-positive cancer cells. We compared the mRNA expression of TRIP13, MAD2L1, and BUB1B to Aurora kinase inhibitor sensitivity. Consistent with our model, higher levels of TRIP13 and lower levels of BUB1B predicted resistance, although the correlation did not reach statistical significance for most of the drugs, likely due to a low sample size (Supplementary Figs. S9A–S9C).

TRIP13 knockdown enhances Aurora kinase inhibition–induced cell death in HPV-positive squamous cancers

TRIP13 is an enzyme that is potentially a therapeutic target. To determine if Aurora kinase and TRIP13 inhibition have synthetic lethality in HPV-positive cancers, first we transfected HPV-positive cell lines with two different siRNAs against TRIP13 that reduced the expression of the TRIP13 mRNA and protein levels (Supplementary Figs. S9D–S9G). Densitometric analysis of the band intensities showed that both siRNAs decreased TRIP13 expression by more than 50% (*, P < 0.001) compared with control siRNA (Supplementary Fig. S9E). Next, we transfected both HPV-positive and HPV-negative cell lines with TRIP13 or control siRNA and treated them with low concentrations of alisertib. TRIP13 knockdown alone did not cause apoptosis, consistent with its effect in other cancer and normal cells (34). We observed higher levels of cleaved caspase-3 and cleaved PARP levels in HPV-positive cells transfected with TRIP13-knockdown with alisertib than in control cells treated with alisertib (Supplementary Fig. S9G), whereas no expression of caspase-3 activation and PARP cleavage were observed in HPV-negative cells (Fig. 6B). In addition, the combination of TRIP13 knockdown with alisertib killed more than half of the cells from five HPV-positive cell lines without significantly affecting HPV-negative squamous cancer cells with
wild-type Rb (Fig. 6C) demonstrating selectivity. In addition, we also observed that the combination led to significant apoptosis in HPV-positive cell lines that were resistant to alisertib (i.e., AOC-LD = 0 in the HTDS) supporting our model (Fig. 6C). To determine if our model was applicable to other cancers with Rb pathway defects, we tested the combination of TRIP13 depletion and Aurora kinase inhibition in non–small cell lung cancer (NSCLC) cell lines with various levels of Rb expression. We found that cancer cells with low Rb levels experienced significantly more apoptosis with the combination than those with high Rb expression (Supplementary Figs. S9H–S9J).

Next, we induced Mad2 overexpression in 2 HPV-positive cell lines to test if altering the balance between TRIP13 and Mad2 would affect cells’ sensitivity to Aurora kinase inhibition. Mad2 overexpression alone did not activate the apoptotic pathways. However, Mad2 overexpression combined with alisertib enhanced apoptosis (Fig. 6D and E).

This study provides strong evidence to support a model in which HPV-positive cancer cells maintain a balance of Mad2 and TRIP13 allowing mitotic exit and survival despite Rb loss. The combined inhibition of TRIP13 and Aurora kinase disrupts the balance and leads...
Figure 5.
The alteration of mitotic checkpoint proteins rescues Rb-depleted cells from Aurora kinase inhibitor–induced apoptosis. 

A, Two HPV-positive cell lines (CASKI and SIHA) were transfected with BUB1B or MAD2L1 siRNA and then treated for 24 hours with 300 nmol/L alisertib before lysis and immunoblotting with the indicated antibodies.

B, TRIP13 was transiently overexpressed (Ox) in 2 HPV-positive cell lines that were treated for 24 hours with 300 nmol/L alisertib before lysis and immunoblotting for the indicated proteins.

C, HPV-positive cell lines with TRIP13 overexpression were treated with 300 nmol/L alisertib for 32 hours and then stained for annexin V-PE/7AAD staining and analysis with flow cytometry to measure apoptosis. The bar graph represents the ratio of apoptosis (late plus early) among different groups. Values are the means ± SDs for three independent experiments (**, P ≤ 0.01; ***P ≤ 0.001; unpaired, two-tailed Student t test).

D, HN31 (left) and MDAMB86LN (right) cells expressing RB1 or control shRNA were transfected with a plasmid for TRIP13. After 24 hours, cells were treated with 300 nmol/L alisertib and then lysed for immunoblotting. Cl, cleaved; Fl, full length.
Figure 6. Disturbing the balance of TRIP13 and MAD2 enhances Aurora kinase inhibition–induced apoptosis. **A**, mRNA expressions of MAD2L1, BUB1B, and TRIP13 in HNSCC HPV-positive (n = 70) and HPV-negative (n = 447) patients with HNSCC tumors from the TCGA (left) and in HPV-positive (n = 51) and HPV-negative OPSCC (n = 28, right). **B** and **C**, TRIP13 was depleted by siRNA in HPV-positive and HPV-negative cell lines. Cells were then treated with 100 nmol/L alisertib for 36 hours before being subjected to (**B**) lysis and immunoblotting with the indicated antibodies or annexin-PE staining to measure apoptosis using flow cytometry (**C**). **D** and **E**, The MAD2L1 plasmid was transiently transfected into two HPV-positive cell lines that were then treated with 100 nmol/L alisertib for 24 hours before being subjected to (**D**) lysis and immunoblotting for the indicated proteins or (**E**) annexin-PE staining to measure apoptosis. Values are the means ± SDs for three independent experiments (∗∗, P ≤ 0.01). Cl, cleaved; Fl, full length; Ox, overexpression. **F**, Model of the synthetic lethality between TRIP13 and Aurora kinase A. HPV-positive, Rb-deficient cancer cells rely on both TRIP13 and Aurora kinase activity to maintain mitotic fidelity, such that their combined inhibition will lead to a prolonged spindle assembly checkpoint (SAC), irreversible mitotic arrest, and cancer cell death.
Ghosh et al.

ATPase family of chaperone proteins, which regulates the SAC by the role of TRIP13 in HPV-positive cells. TRIP13 belongs to the AAA-inhibition and identify a potentially druggable target, we investigated slightly reduced alisertib-induced apoptosis in HPV-positive squamous cells from Aurora kinase inhibitors. Manipulating Rb expression altered sensitivity to Aurora kinase inhibitors. Further, our data identify a novel mechanism in which HPV-positive cancer cells maintain a balance of Mad2 and TRIP13 levels, allowing mitotic exit and survival despite Rb loss and Aurora kinase inhibition. Altering that balance enhanced Aurora kinase inhibition–induced apoptosis. Consistent with this observation, we found that a combination of TRIP13 knockdown with Aurora kinase inhibition led to marked apoptosis in HPV-positive cells, but not in HPV-negative cells that express Rb.

Our in vivo data from three independent PDX models of HPV-driven HNSCC demonstrated not only a striking tumor regression and survival benefit with Aurora kinase inhibition but also a sustained response even after treatment was stopped. McMillan and colleagues were the first to demonstrate that targeting Aurora A dependence on Aurora kinases for their mitotic exit and survival. Cancer cells overexpressing Mad2 have an (active) to an (inactive) form during mitosis (44). TRIP13 localizes to kinetochores, and its knockdown affects the ATPase activity that delays metaphase–anaphase transition. Cancer cells overexpressing Mad2 have an increased dependency on TRIP13 for their mitotic exit (34). Given that Mad2 is overexpressed in HPV-positive patient tumors, we hypothesized that the balance of Mad2 and TRIP13 dictates HPV-positive cancer cells’ dependence on Aurora kinases for their mitotic exit and survival. In this study, TRIP13 knockdown alone did not cause any significant cell death. However, the combined inhibition of TRIP13 and Aurora kinase had a synergistic effect and caused marked apoptosis. Interestingly, Mad2 overexpression enhanced alisertib-induced apoptosis to a lesser degree than did TRIP13 depletion, leading us to speculate that endogenous TRIP13 levels inactivate Mad2 to protect cells. This finding emphasized that Mad2 overexpression increases cells’ dependency on TRIP13 for survival. In Rb-proficient cancers, disrupting mitosis may also affect the efficacy of Aurora kinase inhibition. Aurora kinase inhibitors alone do not cause cell death in HPV-negative HNSCC, but when combined with Wee1 inhibitors led to mitotic catastrophe (45).

Although further work needs to be done to truly understand how the balance of TRIP13 and Mad2 levels mediates sensitivity to Aurora kinase inhibitors, we can take advantage of this relationship as a potential way to effectively target HPV–positive squamous cancer cells while sparing normal cells that express Rb and have unaltered levels of Mad2. The reduction of TRIP13 in normal cells causes only a mild mitotic delay without cell death. Even genetically engineered mice with loss of TRIP13 are viable and grossly normal, although they are smaller than their wild-type counterparts at birth (46). However, we found that, in HPV-positive cancer cells with high endogenous levels of Mad2, combined TRIP13 and Aurora kinase inhibition led to striking levels of apoptosis. These results suggest that TRIP13 could be therapeutically targeted, with potentially low toxicity, in tumors with high Mad2 levels. Given that TRIP13 is an AAA-ATPase, it is a more readily druggable target than Mad2 is. Other AAA-ATPases, such as p97 and ATAD2, are clinically important targets in cancer and have been targeted with small molecules that have shown potential promise in many therapeutic regimens (47).

TRIP13 also functions in DNA repair by promoting nonhomologous end joining (NHEJ) and inducing treatment resistance by binding to the NHEJ proteins KU70, KU80, and DNA-PKcs in head and neck cancer (48). Studies have also suggested that the inhibition of Aurora kinases stimulates the error-prone NHEJ repair of DNA double-strand breaks with increased DNA-PKcs phosphorylation (49). Thus, examining the synergistic effects of TRIP13 and Aurora kinase inhibition, we knocked down TRIP13 expression in cells and treated them with alisertib. TRIP13 inhibition enhanced the cytotoxic effects of alisertib in HPV-positive cells, which suggests that TRIP13 inhibition, in combination with other therapeutics, can reduce cancer cell survival.

Several other biomarkers of sensitivity to Aurora kinase inhibitors have been identified. SCLC cells with MYC amplification or high gene expression frequently respond to Aurora B inhibitors (29), although an independent study demonstrated that neither MYC expression nor amplification is required for sensitivity to Aurora A kinase inhibition in RBl1-mutant SCLC cells (30). One potential mechanism of sensitivity to Aurora kinase inhibition is Myc’s activation of Mad2 and BUBR1 (50). However, in our squamous cancer cell lines, Myc protein expression did not correlate with sensitivity to Aurora kinase inhibitors, which suggests that Rbl1 loss is the more important driver of Mad2 expression. Other potential biomarkers of Aurora kinase inhibitor sensitivity in HNSCC are mutations in KMT2D (lysine methyltransferase 2D; ref. 12), although KMT2D mutations did not correlate with sensitivity in this study, in which cell death, rather than inhibition of proliferation, was used as a metric of drug sensitivity. Previous studies have shown that methyltransferase regulates the SAC complex by directly binding to Mad2 and thereby limiting its availability (51). In HNSCC, mutations in KMT2D may create an imbalance of Mad2 and TRIP13 levels, which would make KMT2D-mutant cells dependent on Aurora kinases for their mitotic exit and survival.

One strength of our study is the use of cell death rather than a reduction in cell proliferation as a measure of drug efficacy. Our metric...
is not affected by the number of cell divisions during the assay. This difference may explain why we and others have identified distinct targets, such as Wee1, PLK1, and HDAC inhibitors, that are more effective in HPV-positive HNSCC using conventional IC50 values (12, 52). One limitation is that we used the same drug concentration range (0.01–3.16 mmol/L) for all the drugs. This range may not have been appropriate for all the drugs in the screen.

To promote rapid translation of our research, we used alisertib for most of our studies because it is a specific inhibitor of Aurora A that is well-tolerated and under active clinical development. Alisertib has an established safety profile in human clinical trials (53–56). Common toxicities include anemia, thrombocytopenia, and neutropenia. Multiple clinical trials using Aurora kinase inhibition have not shown clinical efficacy of single agents in solid tumors. Indeed, even some HPV-positive models experienced only minimal apoptosis with modest, clinically relevant concentrations of alisertib. However, our data demonstrate that the combination the TRIP13 and Aurora kinase inhibition will be effective in HPV-positive cancers. The greatest unmet clinical need is for more effective systemic therapy for patients with recurrent/metastatic HNSCC that is resistant to cisplatin and/or radiotherapy. Several of the cell lines we used are resistant to cisplatin and radiotherapy. In patients with HNSCC who received 100 mg/m2 cisplatin, the plasma concentration range (0.01–3.16 mmol/L), UPCI-SCC-090 (11.1 mmol/L), and UDSCC2 (18 mmol/L; ref. 59). In addition, SiHa and UPCI-SCC-090 are resistant to radiotherapy (58, 60).

The data presented herein show that Aurora kinase and TRIP13 have synthetic lethality specifically in HPV-driven squamous cancer cells because the cells’ loss of Rb protein expression leads to high Mad2 expression. HPV-positive tumors from patients with HNSCC also exhibited high levels of Mad2 expression. This cancer cell–specific effect allowed us to reduce the concentration of alisertib needed for treatment. These results suggest that the combination of TRIP13 and Aurora kinase inhibition provides a wider therapeutic window than classic cytotoxic agents do for the treatment of HPV-positive squamous cell carcinoma. This combination could help meet an urgent unmet need to reduce mortality and long-term treatment-related toxicity among patients with HPV-driven cancers. The findings may also be applicable to the treatment of patients with other cancers with Rb pathway defects, including NSCLC (61).

Authors’ Disclosures

C. Stephan reports grants from Cancer Prevention and Research Institute of Texas during the conduct of the study. C.R. Pickering reports grants from NIH outside the submitted work. F.M. Johnson reports grants from Takeda, Viracatra, and Trovagene outside the submitted work. No disclosures were reported by the other authors.

Authors’ Contributions

S. Ghosh: Conceptualization, funding acquisition, validation, investigation, visualization, methodology, writing—original draft, project administration, writing—review and editing. T. Mazumdar: Investigation, W. Xu: Investigation, methodology. R.T. Powell: Data curation, investigation, methodology. C. Stephan: Data curation, software. L. Shen: Data curation, software. P.A. Shah: Data curation, investigation. C.R. Pickering: Data curation, software, investigation. J.N. Myers: Resources, data curation, software. J. Wang: Resources, data curation, software, supervision.

M.J. Frederick: Data curation, software, supervision, writing—review and editing. F.M. Johnson: Conceptualization, funding acquisition, project administration, writing—review and editing.

Acknowledgments

This work was supported by the NIH (RO1CA248205; to F.M. Johnson); philanthropic contributions from Mr. and Mrs. Charles W. Stiefel to The University of Texas MD Anderson Cancer Center–Oropharynx Cancer Program (to F.M. Johnson, C.R. Pickering); and the Cancer Prevention and Research Institute of Texas (RP150578; to C. Stephan). This work used the services of MD Anderson’s Flow Cytometry and Cellular Imaging Facility and Bioinformatics Shared Resource, which are supported by the NIH through MD Anderson’s Cancer Center Support Grant (P30CA016672). We would like to thank all members of the Flow Cytometry & Cellular Imaging facility, which is supported in part by the NIH through MD Anderson’s Cancer Center Support Grant CA016672. We would also like to thank Laura L. Russell, scientific editor of MD Anderson, Research Medical Library, for editing this article.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note

Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

Received May 19, 2022; revised July 11, 2022; accepted August 11, 2022; published first August 16, 2022.